IN2014CN00989A - - Google Patents
Info
- Publication number
- IN2014CN00989A IN2014CN00989A IN989CHN2014A IN2014CN00989A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A IN 989CHN2014 A IN989CHN2014 A IN 989CHN2014A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A
- Authority
- IN
- India
- Prior art keywords
- compounds
- treprostinil
- pah
- prodrugs
- covalent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177409 | 2011-08-12 | ||
| EP11195615 | 2011-12-23 | ||
| EP12165508 | 2012-04-25 | ||
| PCT/EP2012/065745 WO2013024052A1 (en) | 2011-08-12 | 2012-08-10 | Carrier-linked treprostinil prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN00989A true IN2014CN00989A (uk) | 2015-04-10 |
Family
ID=46690494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN989CHN2014 IN2014CN00989A (uk) | 2011-08-12 | 2012-08-10 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9561287B2 (uk) |
| EP (1) | EP2741781A1 (uk) |
| JP (1) | JP6092867B2 (uk) |
| KR (1) | KR101997939B1 (uk) |
| CN (1) | CN103857413A (uk) |
| AU (1) | AU2012296954B2 (uk) |
| BR (1) | BR112014003225A2 (uk) |
| CA (1) | CA2843883C (uk) |
| HK (1) | HK1198359A1 (uk) |
| IL (1) | IL230712A (uk) |
| IN (1) | IN2014CN00989A (uk) |
| MX (1) | MX349950B (uk) |
| WO (1) | WO2013024052A1 (uk) |
| ZA (1) | ZA201400977B (uk) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012296954B2 (en) * | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
| US20150087688A1 (en) * | 2012-04-25 | 2015-03-26 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| EP2928501B1 (en) | 2012-12-07 | 2020-05-06 | Ascendis Pharma A/S | Carrier-linked prostanoid prodrugs |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| ES2927844T3 (es) | 2013-01-11 | 2022-11-11 | Corsair Pharma Inc | Profármacos de treprostinil |
| KR102238501B1 (ko) * | 2013-03-25 | 2021-04-08 | 유나이티드 세러퓨틱스 코오포레이션 | 링커 티올 및 peg화된 형태를 갖는 프로스타시클린 화합물의 제조 방법 |
| CN105407883A (zh) | 2013-04-30 | 2016-03-16 | 联合治疗学有限公司 | 控释药物制剂 |
| CN108947843A (zh) | 2013-10-25 | 2018-12-07 | 英斯梅德股份有限公司 | 前列环素化合物、其组合物及使用方法 |
| JO3624B1 (ar) * | 2014-05-08 | 2020-08-27 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| JP2017517550A (ja) * | 2014-06-13 | 2017-06-29 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニル製剤 |
| WO2016010538A1 (en) * | 2014-07-16 | 2016-01-21 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| JP6866043B2 (ja) | 2014-11-18 | 2021-04-28 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 |
| TWI540121B (zh) | 2014-12-01 | 2016-07-01 | 臺灣永光化學工業股份有限公司 | 曲前列環素二乙醇胺之合成方法及新穎中間體 |
| EP3226838A1 (en) | 2014-12-03 | 2017-10-11 | Steadymed Ltd. | Preservative-free treprostinil formulations and methods and devices for use with same |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| EP3400022A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low initial npr-b activity |
| WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| WO2017118693A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| AU2017205273C1 (en) | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| BR112018011008A2 (pt) | 2016-01-08 | 2018-12-04 | Ascendis Pharma Growth Disorders As | agonistas de cnp de liberação controlada com ligação a npr-c baixa |
| EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| JP7059195B2 (ja) | 2016-03-01 | 2022-04-25 | アセンディス ファーマ ボーン ディジージズ エー／エス | Ｐｔｈプロドラッグ |
| US11896671B2 (en) | 2016-07-13 | 2024-02-13 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| CA3036307A1 (en) * | 2016-09-15 | 2018-03-22 | Camurus Ab | Prostacyclin analogue formulations |
| KR20230170810A (ko) | 2016-09-29 | 2023-12-19 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
| KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
| KR20240013849A (ko) | 2016-09-29 | 2024-01-30 | 아센디스 파마 본 디지즈 에이/에스 | 조절 방출 pth 화합물을 위한 투여 용법 |
| WO2018060311A1 (en) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Incremental dose finding in controlled-release pth compounds |
| EP3498283A1 (en) | 2017-12-14 | 2019-06-19 | Ipsol AG | Glycosidic derivatives of treprostinil |
| SG11202010387QA (en) | 2018-05-18 | 2020-11-27 | Ascendis Pharma Bone Diseases As | Starting dose of pth conjugates |
| EP3856257A1 (en) | 2018-09-26 | 2021-08-04 | Ascendis Pharma A/S | Degradable hyaluronic acid hydrogels |
| WO2020064846A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Novel hydrogel conjugates |
| CA3114056A1 (en) | 2018-09-26 | 2020-04-02 | Ascendis Pharma A/S | Treatment of infections |
| TW202042844A (zh) | 2019-01-04 | 2020-12-01 | 丹麥商阿仙帝斯製藥公司 | 模式辨別受體(pattern recognition receptor)促效劑的共軛物 |
| KR20210113272A (ko) | 2019-01-04 | 2021-09-15 | 아센디스 파마 온콜로지 디비전 에이/에스 | 선천 면역 작용제를 위한 지속되는 국소 약물 수준 |
| EP3906018A1 (en) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| WO2020141225A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma A/S | Minimization of systemic inflammation |
| CN113423383A (zh) | 2019-02-11 | 2021-09-21 | 阿森迪斯药物骨疾病股份有限公司 | Pth缀合物的液体药物制剂 |
| JP2022520193A (ja) | 2019-02-11 | 2022-03-29 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | Ｃｎｐコンジュゲートの乾燥医薬製剤 |
| WO2020223237A1 (en) | 2019-04-29 | 2020-11-05 | Insmed Incorporated | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
| AU2020295724A1 (en) | 2019-06-21 | 2021-12-02 | Ascendis Pharma Oncology Division A/S | Tyrosine kinase inhibitor conjugates |
| WO2020254617A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pk properties |
| WO2020254613A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pk properties |
| WO2020254607A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Anti-ctla4 compounds with localized pd properties |
| WO2020254612A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma Oncology Division A/S | Controlled-release tyrosine kinase inhibitor compounds with localized pd properties |
| TW202114738A (zh) | 2019-06-21 | 2021-04-16 | 丹麥商阿仙帝斯製藥公司 | 抗ctla4結合物 |
| JP2020011957A (ja) * | 2019-07-22 | 2020-01-23 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| JP2023510790A (ja) | 2020-01-13 | 2023-03-15 | アセンディス ファーマ ボーン ディジージズ エー／エス | 副甲状腺機能低下症の治療 |
| US20230241217A1 (en) | 2020-05-04 | 2023-08-03 | Ascendis Pharma A/S | Hydrogel irradiation |
| JP2023529828A (ja) | 2020-06-09 | 2023-07-12 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルのフマリルジケトピペリジンプロドラッグ |
| AU2021349316A1 (en) | 2020-09-28 | 2023-04-27 | Ascendis Pharma Bone Diseases A/S | Improvement of physical and mental well-being of patients with hypoparathyroidism |
| JP7138685B2 (ja) * | 2020-10-26 | 2022-09-16 | コルセア ファーマ インコーポレイテッド | トレプロスチニル誘導体化合物およびその使用方法 |
| TW202246206A (zh) * | 2021-03-16 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種曲前列環素衍生物及其用途 |
| CA3230895A1 (en) | 2021-09-22 | 2023-03-30 | Kennett Sprogoe | Long-acting pth compound treatments |
| AU2022409306A1 (en) | 2021-12-13 | 2024-06-06 | Ascendis Pharma Oncology Division A/S | Cancer treatments with tlr7/8 agonists |
| AU2022413318A1 (en) | 2021-12-13 | 2024-05-16 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| CN116444377A (zh) * | 2022-01-07 | 2023-07-18 | 广州楷石医药有限公司 | 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途 |
| WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
| WO2024094673A1 (en) | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306075A (en) | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| CA2359652A1 (en) * | 1999-03-31 | 2000-10-05 | United Therapeutics Corporation | Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension |
| JP4698579B2 (ja) * | 2003-04-08 | 2011-06-08 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的ｐｅｇ化薬物 |
| CN1917883B (zh) * | 2003-12-16 | 2011-05-11 | 联合治疗公司 | 曲前列环素在制备改善肾功能的药物中的用途 |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| EP1625856A1 (en) | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel polymeric conjugates of a prodrug |
| WO2008098196A1 (en) * | 2007-02-09 | 2008-08-14 | United Therapeutics Corporation | Treprostinil treatment for interstitial lung disease and asthma |
| NZ580670A (en) | 2007-06-21 | 2011-09-30 | Univ Muenchen Tech | Biological active proteins having increased in vivo and/or vitro stability |
| ES2587400T3 (es) | 2008-04-29 | 2016-10-24 | Ascendis Pharma Growth Disorders Division A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
| US8575102B2 (en) | 2008-08-01 | 2013-11-05 | Nektar Therapeutics | Conjugates having a releasable linkage |
| MX2011001583A (es) * | 2008-08-11 | 2011-04-04 | Nektar Therapeutics | Conjugados de alcanoato polimericos de multiples brazos. |
| MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
| WO2010068754A2 (en) | 2008-12-10 | 2010-06-17 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
| EP2440228B8 (en) * | 2009-06-08 | 2023-02-22 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| CA2769162C (en) * | 2009-07-31 | 2017-12-05 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| US20130053405A1 (en) * | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
| AU2012296954B2 (en) * | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
-
2012
- 2012-08-10 AU AU2012296954A patent/AU2012296954B2/en not_active Ceased
- 2012-08-10 KR KR1020147006343A patent/KR101997939B1/ko active IP Right Grant
- 2012-08-10 JP JP2014524413A patent/JP6092867B2/ja not_active Expired - Fee Related
- 2012-08-10 IN IN989CHN2014 patent/IN2014CN00989A/en unknown
- 2012-08-10 BR BR112014003225A patent/BR112014003225A2/pt not_active Application Discontinuation
- 2012-08-10 WO PCT/EP2012/065745 patent/WO2013024052A1/en active Application Filing
- 2012-08-10 CN CN201280049725.9A patent/CN103857413A/zh active Pending
- 2012-08-10 CA CA2843883A patent/CA2843883C/en not_active Expired - Fee Related
- 2012-08-10 MX MX2014001497A patent/MX349950B/es active IP Right Grant
- 2012-08-10 US US14/238,437 patent/US9561287B2/en active Active
- 2012-08-10 EP EP12748194.3A patent/EP2741781A1/en not_active Withdrawn
-
2014
- 2014-01-29 IL IL230712A patent/IL230712A/en active IP Right Grant
- 2014-02-10 ZA ZA2014/00977A patent/ZA201400977B/en unknown
- 2014-11-24 HK HK14111870A patent/HK1198359A1/xx unknown
-
2017
- 2017-01-27 US US15/418,180 patent/US10729778B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2843883A1 (en) | 2013-02-21 |
| WO2013024052A1 (en) | 2013-02-21 |
| CN103857413A (zh) | 2014-06-11 |
| HK1198359A1 (en) | 2015-04-10 |
| US9561287B2 (en) | 2017-02-07 |
| AU2012296954A1 (en) | 2014-02-20 |
| EP2741781A1 (en) | 2014-06-18 |
| US10729778B2 (en) | 2020-08-04 |
| JP6092867B2 (ja) | 2017-03-08 |
| US20140296150A1 (en) | 2014-10-02 |
| ZA201400977B (en) | 2017-11-29 |
| MX2014001497A (es) | 2014-04-25 |
| BR112014003225A2 (pt) | 2017-03-01 |
| IL230712A (en) | 2017-08-31 |
| JP2014527050A (ja) | 2014-10-09 |
| KR20140070545A (ko) | 2014-06-10 |
| KR101997939B1 (ko) | 2019-07-08 |
| US20190105400A1 (en) | 2019-04-11 |
| MX349950B (es) | 2017-08-22 |
| CA2843883C (en) | 2020-04-28 |
| AU2012296954B2 (en) | 2016-09-15 |
| IL230712A0 (en) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN00989A (uk) | ||
| PH12017501426A1 (en) | Derivatives of betulin | |
| WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
| MY170713A (en) | Treatment protocol of diabetes type 2 | |
| MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| MY187718A (en) | Pharmaceutical formulations | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| IN2012DN02139A (uk) | ||
| TN2011000585A1 (en) | Lxr modulators | |
| TN2014000112A1 (en) | Ep1 receptor ligands | |
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| MX2011011776A (es) | Nuevos profarmacos de triptolite. | |
| IN2014CN04449A (uk) | ||
| WO2013093931A3 (en) | Novel prodrugs of phenolic drugs | |
| WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
| IN2013DN02555A (uk) | ||
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
| WO2012176163A3 (en) | Compounds for the treatment of cancers associated with human papillomavirus | |
| MX2013002656A (es) | Nuevo proceso. |